SCHEMBL19994499

SCHEMBL19994499

Nc1ccc(-c2nc3ccc(C(=O)c4ccccc4)cc3[nH]2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 10/20 0.79
KMT2A Q03164 2/20 0.78
MEN1 O00255 1/20 0.78
ABL1 P00519 1/20 0.67
FABP6 P51161 1/20 0.67
PKM P14618 1/20 0.64
ESR1 P03372 1/20 0.62
MAPT P10636 3/20 0.62
KDM4E B2RXH2 2/20 0.62
ALDH1A1 P00352 2/20 0.62
NPC1 O15118 1/20 0.62
GLA P06280 1/20 0.62
GAA P10253 1/20 0.62
HPGD P15428 1/20 0.62
HTT P42858 1/20 0.62
RAB9A P51151 1/20 0.62
GFER P55789 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
RCE1 Q9Y256 1/20 0.62
CYP2C9 P11712 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19994652 1.00 CHEK2 (0.79) CHEK2KMT2AMEN1ABL1FABP6
SCHEMBL2243148 0.91 CHEK2 (0.80) CHEK2KMT2AMEN1ABL1FABP6
SCHEMBL19994452 0.90 CHEK2 (0.64) CHEK2KMT2AMEN1ABL1FABP6
SCHEMBL5679988 0.88 CHEK2 (1.00) CHEK2
SCHEMBL5675969 0.88 CHEK2 (0.81) CHEK2KMT2AMEN1PKMESR1
SCHEMBL27765862 0.88 CHEK2 (0.78) CHEK2KMT2AMEN1ABL1FABP6
SCHEMBL29576909 0.87 NR4A2 (0.75) CHEK2KMT2AMEN1PKMMAPT
SCHEMBL28384472 0.87 NR4A2 (0.75) CHEK2KMT2AMEN1PKMMAPT
SCHEMBL31289463 0.86 CHEK2 (0.65) CHEK2KMT2AMEN1ABL1FABP6
SCHEMBL19994477 0.83 CHEK2 (0.79) CHEK2KMT2AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509465-B2 Benzoimidazole derivatives as anticancer agents CENTRE LEON BERARD (FR) 2025-12-30 US disclosed
EP-3515904-B1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2024-01-17 EP disclosed
CN-110234640-B Benzimidazole derivatives as anticancer agents 利昂贝拉尔中心 2023-04-07 CN disclosed
US-20220348587-A1 Benzoimidazole Derivatives As Anticancer Agents CENTRE LEON BERARD (FR) 2022-11-03 US disclosed
US-11384081-B2 Benzoimidazole derivatives as anticancer agents CENTRE LEON BERARD (FR) 2022-07-12 US disclosed
US-20210292328-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2021-09-23 US disclosed
EP-3515904-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS Centre Leon Berard (FR) 2019-07-31 EP disclosed
WO-2018054989-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509465-B2 Benzoimidazole derivatives as anticancer agents CCAR2, MAPKAP1, BCOR CHEK2 369/4885KMT2A 3941/4885MEN1 4170/4885
US-20210292328-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS TMBIM6, BAX, MAPK14 CHEK2 164/4885KMT2A 3022/4885MEN1 4272/4885
US-11384081-B2 Benzoimidazole derivatives as anticancer agents TMBIM6, BAX, MAPK14 CHEK2 164/4885KMT2A 3022/4885MEN1 4272/4885
US-20220348587-A1 Benzoimidazole Derivatives As Anticancer Agents TMBIM6, BAX, BCL2 CHEK2 169/4885KMT2A 3028/4885MEN1 4350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.